(香港，2025 年 12 月 23 日)– 专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器 械的全 14 支直销团队，加上逾 300 家分销商组成了强大的销售引擎，不仅将我们创新的优质介入医疗器械带 到全球超过 70 个 国家及地区，更能协助中国医疗器械制造商拓展国际市场。此次获奖我们感到非常荣幸，也肯定了我们 的信念：跨越市 场的深度融合，是企业达到可持续发展的关键因素。" 格隆汇以"全球视野，下注中国"为初衷，设立"金格奖"年度卓越公司评选，以建立投资圈中最具参考价 值的上市公司及 球医疗器械公司业聚医疗集团控股有限公司("业聚医疗"或"集团"；股份代号：6929)于格隆汇 2025 年 度"金格奖"卓越 公司评选中荣获"年度卓越出海奖"，彰显了集团凭借高瞻远瞩、创新能力与卓越执行力，于跨境合作领 域展现出卓越的 国际影响力与成就。 业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示："过去二十多年来，我们一直致力研发创新 介入治疗方案， 同时建立了以中国、日本、德国及荷兰为研发、制造与物流基地的全球网络，提升供应链的抗逆能力。 此外，我们遍布 比利时、法国、德国、香港、澳门 ...

"年度卓越出海奖"旨在表彰那些在过去一年中，凭借前瞻视野、创新模式与卓越执行力，在全球化资本 运作中取得突破性成就的机构、企业或关键项目。获奖公司不仅高效配置全球资源，更通过资本纽带， 深度融入国际产业链，提升了中国企业在全球市场中的品牌价值、定价权与行业话语权。 | 1 | | 2025年度卓越公司评选榜单 | DD | | --- | --- | --- | --- | | | | CLUB OUTSTANDING COMPANIES LIST 2026 | | | 公司名称 | 公司代码 | 公司名称 | 公司代码 | | 爱奇艺 | IQ.US | 盛亦 | 06069.HK | | 菜鸟 | | 玄武云 | 02392.HK | | ાઉદ | 00799.HK | 业聚医疗 | 06929.HK | | 极光 | JG.US | 中国联盟 | 02128.HK | | 零跑汽车 | 09863.HK | 中文在线 | 300364.SZ | | | | 排名不分先后 | | 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角 兽公司排行榜。此次"金格奖"上 ...

"年度卓越出海奖"旨在表彰那些在过去一年中，凭借前瞻视野、创新模式与卓越执行力，在全球化资本 运作中取得突破性成就的机构、企业或关键项目。获奖公司不仅高效配置全球资源，更通过资本纽带， 深度融入国际产业链，提升了中国企业在全球市场中的品牌价值、定价权与行业话语权。 | 1 | | 2025年度卓越公司评选榜单 | DD | | --- | --- | --- | --- | | | | CLUB OUTSTANDING COMPANIES LIST 2026 | | | 公司名称 | 公司代码 | 公司名称 | 公司代码 | | 爱奇艺 | IQ.US | 盛亦 | 06069.HK | | 菜鸟 | | 玄武云 | 02392.HK | | ાઉદ | 00799.HK | 业聚医疗 | 06929.HK | | 极光 | JG.US | 中国联盟 | 02128.HK | | 零跑汽车 | 09863.HK | 中文在线 | 300364.SZ | | | | 排名不分先后 | | 12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜 单将隆重揭晓，其中格隆汇" ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 本月底法定/註冊股本總額： USD 600,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊 ...

Group 1 - The core point of the article is that Yejv Medical (6929.HK) has completed the structural topping of its R&D and production facility in Fuyang, Hangzhou, which is set to be the largest integrated facility globally, with full production expected by 2027 [1] - The new facility will add approximately 2.4 million units of production capacity annually, increasing the total annual output from the current 2.1 million units of balloons and stents [1] - The company currently operates R&D centers, production bases, and logistics hubs in China, Germany, Japan, and the Netherlands, and has a sales network covering over 70 countries and regions [1][1] Group 2 - Yejv Medical holds over 250 authorized patents and has announced patent applications, with more than 55 approved products sold in major global markets [1][1] - The completion of the Hangzhou facility is expected to significantly enhance the company's high-quality production capacity, accelerate the incubation and application of new technologies, and improve the stability of the global supply chain and overall competitiveness [1] - The company aims to capitalize on the continuous growth opportunities in the global PCI and PTA device markets [1]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股 ...

[Company Information](index=4&type=section&id=Company%20Information) This section provides essential details about OrbusNeich Medical Group Holdings Limited, including its board members, committees, registered office, and auditor [Company Basic Information](index=4&type=section&id=Company%20Basic%20Information) This section provides basic information about OrbusNeich Medical Group Holdings Limited, including its board members, audit committee, remuneration committee, nomination committee, authorized representatives, company secretary, registered office, company headquarters, principal place of business in Hong Kong, share registrar, legal advisers, auditor, principal bankers, stock code, and company website - Board members include Executive Directors Mr. Qian Yongxun, Ms. Liu Guizhen, Mr. Chen Yongcheng; Non-executive Directors Mr. Liang Dingxin, Dr. Zhou Yi, Mr. Zhou Jingzhong (resigned); Independent Non-executive Directors Mr. Chen Yeqiang, Mr. Lou Jiaqiang, Dr. Tan Lifen[8](index=8&type=chunk) - The company's registered office is in the Cayman Islands, with its headquarters and principal place of business in Hong Kong located in Hong Kong Science Park[8](index=8&type=chunk) - The auditor is PricewaterhouseCoopers, stock code is **6929**, and the company website is https://orbusneich.com/[10](index=10&type=chunk) [Financial Highlights](index=6&type=section&id=Financial%20Highlights) This section summarizes the Group's financial performance, highlighting revenue growth, profit for the period, and key profitability ratios [Operating Results and Profitability](index=6&type=section&id=Operating%20Results%20and%20Profitability) For the six months ended June 30, 2025, the company's revenue increased by 5.9% year-on-year to USD 83,550 thousand, but gross margin decreased by 3.8 percentage points to 66.9%; profit for the period attributable to owners of the company grew by 5.1% to USD 19,785 thousand, with basic earnings per share at 2.40 US cents For the six months ended June 30, Operating Results and Profitability | Metric | 2025 (USD thousands) | 2024 (USD thousands) | Change (%) | Change (percentage points) | | :--- | :--- | :--- | :--- | :--- | | Revenue | 83,550 | 78,910 | 5.9% | - | | Cost of Sales | (27,653) | (23,134) | 19.5% | - | | Gross Profit | 55,897 | 55,776 | 0.2% | - | | Profit Before Income Tax | 20,775 | 21,285 | -2.4% | - | | Profit for the Period Attributable to Owners of the Company | 19,785 | 18,828 | 5.1% | - | | Basic EPS (US cents) | 2.40 | 2.28 | 5.3% | - | | Diluted EPS (US cents) | 2.40 | 2.28 | 5.3% | - | | Gross Margin | 66.9% | 70.7% | - | -3.8% | | Net Margin | 23.7% | 23.9% | - | -0.2% | [Management Discussion and Analysis](index=7&type=section&id=Management%20Discussion%20and%20Analysis) This section provides a comprehensive review of the Group's business operations, financial performance, strategic outlook, and capital management for the reporting period [Business Review](index=7&type=section&id=Business%20Review) OrbusNeich Medical is a global medical device company specializing in PCI and PTA interventional devices, headquartered in Hong Kong, with products sold in over 70 countries and regions worldwide; in H1 2025, despite macroeconomic and geopolitical challenges, the company's revenue grew by 5.9%, driven by strong growth in Asia Pacific and EMEA markets, partially offset by declines in Japan and China, while actively expanding its direct sales model and investing in product development and manufacturing facilities - OrbusNeich Medical specializes in PCI and PTA interventional devices, with products sold in over **70** countries and regions globally, and is actively expanding into the structural heart disease field[14](index=14&type=chunk) - In H1 2025, the Group's revenue reached **USD 83.6 million**, a year-on-year increase of **5.9%**, with proprietary product sales growing by **8.6%** year-on-year[15](index=15&type=chunk) - Profit attributable to owners of the Company was **USD 19.8 million**, a year-on-year increase of **5.1%**; the Board declared a special dividend of **HK 15 cents** per ordinary share to celebrate the Group's 25th anniversary[16](index=16&type=chunk) [Performance by Geographical Market](index=7&type=section&id=Performance%20by%20Geographical%20Market) The Asia Pacific and Europe, Middle East & Africa markets showed strong performance, with revenue growth of 14.0% and 17.0% respectively; the US market also saw significant growth of 20.0% despite tariff impacts, while Japan and Mainland China experienced revenue declines of 14.8% and 5.1% due to sales strategy adjustments and volume-based procurement For the six months ended June 30, Revenue Performance by Geographical Market | Region | 2025 (USD thousands) | 2024 (USD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Asia Pacific | 27,311 | 23,955 | 14.0% | | Europe, Middle East & Africa | 22,429 | 19,170 | 17.0% | | Japan | 16,114 | 18,908 | -14.8% | | Mainland China | 9,652 | 10,176 | -5.1% | | United States | 8,044 | 6,701 | 20.0% | | **Total** | **83,550** | **78,910** | **5.9%** | - Revenue in the Asia Pacific region significantly increased by **14.0%**, primarily due to strong growth in the Indonesian market and widespread adoption of Scoreflex TRIO in Singapore and Malaysia[17](index=17&type=chunk) - Revenue in Europe, Middle East, and Africa (EMEA) significantly rose by **17.0%**, mainly driven by increased sales of proprietary balloon products in direct sales markets (e.g., Germany, France, Spain) and distribution markets (e.g., UK, Slovakia, Czech Republic)[18](index=18&type=chunk) - Revenue in Japan decreased by **14.8%** year-on-year, primarily due to adjusted sales strategy, shifting focus away from lower-priced coronary balloon products, leading to a decline in sales volume[19](index=19&type=chunk) - Revenue in Mainland China decreased by **5.1%** year-on-year, mainly due to a decline in average selling prices caused by the volume-based procurement program, despite an increase in sales volume of conventional balloon products[20](index=20&type=chunk) - Revenue in the US market significantly increased by **20.0%**, primarily due to a notable rise in sales volume of conventional and scoring coronary balloons, and peripheral balloons (including high-value Scoreflex NC balloons)[21](index=21&type=chunk) [Operations Summary](index=8&type=section&id=Operations%20Summary) The company's strategy focuses on enhancing brand value through a direct sales model and extensive distributor network covering over 70 countries and regions globally; in H1 2025, the company acquired a Taiwanese distributor, transitioning the Taiwan market to a direct sales model and increasing its direct sales team to 13; the company continues to invest in R&D, holding over 250 granted patents, with several new products receiving regulatory approvals or entering clinical trials; global manufacturing facilities include a new Hangzhou facility expected to be operational by 2027, significantly boosting production capacity - The company covers over **70** countries and regions through its direct sales team and distributor network; in H1 2025, it acquired a Taiwanese distributor, transitioning the Taiwan market to a direct sales model, increasing the direct sales team to **13**[23](index=23&type=chunk) - As of June 30, 2025, the Group had **286** sales and marketing personnel (December 31, 2024: 266), with direct sales and distributor sales contributing **57.7%** and **42.3%** of total revenue, respectively[23](index=23&type=chunk) - The Group holds over **250** granted patents and published patent applications in major global jurisdictions, with several products having obtained CE Mark, PMDA, or FDA approvals[27](index=27&type=chunk)[28](index=28&type=chunk) - The company has manufacturing facilities in multiple global locations, including Shenzhen (China), Hoofddorp (Netherlands), and Weil am Rhein (Germany); the largest R&D and manufacturing facility in Hangzhou is expected to be operational by **2027**, increasing annual production capacity by approximately **2.4 million units**[29](index=29&type=chunk) [Third-Party Product Collaboration](index=9&type=section&id=Third-Party%20Product%20Collaboration) OrbusNeich Medical expanded its exclusive distribution agreement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ("Mindray Medical") to include intravascular ultrasound (IVUS) products, extending the collaboration from Hong Kong and Macau to direct sales markets such as Singapore, Malaysia, France, Germany, Spain, and Switzerland, and covering six additional distribution markets in Europe - The exclusive distribution agreement with Kaili Medical has been expanded to direct sales markets including Singapore, Malaysia, France, Germany, Spain, and Switzerland, and covers six additional distribution markets in Europe for its IVUS products[26](index=26&type=chunk) [Joint Ventures](index=10&type=section&id=Joint%20Ventures) The joint venture OrbusNeich P&F focuses on developing innovative structural heart products, with TricValve's clinical trials in Mainland China progressing well, expanding to 21 participating institutions and achieving its first commercial application in July; the joint venture also boasts a pipeline of structural heart interventional devices - Joint venture OrbusNeich P&F focuses on innovative structural heart products; TricValve's clinical trials in Mainland China have expanded to **21** participating institutions and achieved its first commercial application in Mainland China in **July 2025**[30](index=30&type

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股本 ...

Core Viewpoint - The company reported its 1H25 performance, showing revenue and net profit growth, with a stable profitability outlook despite regional challenges [1][2]. Financial Performance - 1H25 revenue reached $83.55 million, a year-on-year increase of 5.9% - Net profit attributable to shareholders was $19.79 million, up 5.1% year-on-year - The performance aligns with the company's expectations [1]. Regional Growth Trends - Asia-Pacific (excluding China and Japan) revenue grew by 14%, driven by rapid growth in Indonesia and benefits from the Scoreflex TRIO balloon's market expansion - EMEA revenue increased by 17% - Japan's revenue declined by 15% due to a shift in sales strategy and reduced sales of low-priced coronary balloons, although sales expenses were significantly reduced - Revenue in China fell by 5%, with an increased proportion of revenue from centralized procurement products - U.S. revenue rose by 20%, despite tariff disruptions, with a positive outlook for coronary and peripheral balloon products in 2024 [1]. Profitability and Cost Management - 1H25 gross margin was 66.9%, down 3.8 percentage points year-on-year, attributed to declining sales in Japan and price reductions in China - Sales and management expense ratios decreased, while R&D expense ratios remained stable, leading to a stable net profit margin [1]. Global Business Network and Product Introduction - The company has established a mature and reliable direct sales team in over a dozen countries in Europe and Asia-Pacific - Recent acquisitions of distributors in Indonesia, South Korea, and Taiwan aim to enhance direct sales - The company has partnered with KaiLi Medical to distribute IVUS products in multiple regions, indicating a strong potential for introducing high-quality products [2]. Earnings Forecast and Valuation - The company maintains its earnings forecast for 2025/26, with a current price corresponding to a P/E ratio of 12/11 times - The target price has been raised by 36% to HKD 6.4, reflecting a 29% upside potential based on the overall recovery of the Hong Kong medical device sector and confidence in the company's global sales network [2].